Technical Analysis for TPTX - Turning Point Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 56.99 -2.91% -1.71
TPTX closed down 2.91 percent on Friday, August 7, 2020, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical TPTX trend table...

Date Alert Name Type % Chg
Earnings Movers Other 0.00%
Multiple of Ten Bearish Other 0.00%
Outside Day Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
NR7 Range Contraction -2.91%
Earnings Movers Other -2.91%
Oversold Stochastic Weakness -2.91%
Lower Bollinger Band Touch Weakness -1.50%
Oversold Stochastic Weakness -1.50%
180 Bearish Setup Bearish Swing Setup -2.15%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Medicine Cancer Treatment Of Cancer Oncology Chemical Compounds Solid Tumors Non Small Cell Lung Cancer Antineoplastic Drugs Cancer Treatment Targeted Therapy Cancer Therapies Signal Transduction Pyrrolidines Protein Kinase Inhibitors Kinase

Is TPTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 72.025
52 Week Low 31.3042
Average Volume 284,215
200-Day Moving Average 55.20
50-Day Moving Average 63.39
20-Day Moving Average 61.38
10-Day Moving Average 59.73
Average True Range 3.42
ADX 11.5
+DI 14.73
-DI 16.87
Chandelier Exit (Long, 3 ATRs ) 59.50
Chandelier Exit (Short, 3 ATRs ) 66.76
Upper Bollinger Band 66.32
Lower Bollinger Band 56.44
Percent B (%b) 0.06
BandWidth 16.10
MACD Line -1.34
MACD Signal Line -0.84
MACD Histogram -0.4989
Fundamentals Value
Market Cap 920.61 Million
Num Shares 16.2 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -42.88
Price-to-Sales 0.85
Price-to-Book 1.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 63.20
Resistance 3 (R3) 63.73 62.19 62.17
Resistance 2 (R2) 62.19 60.61 61.93 61.82
Resistance 1 (R1) 59.59 59.63 58.82 59.06 61.47
Pivot Point 58.05 58.05 57.67 57.79 58.05
Support 1 (S1) 55.45 56.47 54.68 54.92 52.51
Support 2 (S2) 53.91 55.49 53.65 52.16
Support 3 (S3) 51.31 53.91 51.82
Support 4 (S4) 50.78